PTEN and cancer: Mir-19a was first identified as the key oncogenic component of the miR-17-92 cluster, which is frequently amplified or over-expressed in human cancers [40] and exerts oncogenic activity by suppressing Phosphatase and tensin homolog (PTEN) [41] or by modulating the oncogenic properties of c-Myc [42].